(R)-[(11)C]verapamil is Selectively Transported by Murine and Human P-glycoprotein at the Blood-brain Barrier, and Not by MRP1 and BCRP

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2013 Jul 13

PMID 23845421

Citations 35

Authors

Kerstin Romermann

Thomas Wanek

Marion Bankstahl

Jens P Bankstahl

Maren Fedrowitz

Markus Muller

Wolfgang Loscher

Claudia Kuntner

Oliver Langer

Affiliations

Soon will be listed here.

Abstract

Introduction: Positron emission tomography (PET) with [(11)C]verapamil, either in racemic form or in form of the (R)-enantiomer, has been used to measure the functional activity of the adenosine triphosphate-binding cassette (ABC) transporter P-glycoprotein (Pgp) at the blood-brain barrier (BBB). There is some evidence in literature that verapamil inhibits two other ABC transporters expressed at the BBB, i.e. multidrug resistance protein 1 (MRP1) and breast cancer resistance protein (BCRP). However, previous data were obtained with micromolar concentrations of verapamil and do not necessarily reflect the transporter selectivity of verapamil at nanomolar concentrations, which are relevant for PET experiments. The aim of this study was to assess the selectivity of verapamil, in nanomolar concentrations, for Pgp over MRP1 and BCRP.

Methods: Concentration equilibrium transport assays were performed with [(3)H]verapamil (5 nM) in cell lines expressing murine or human Pgp, human MRP1, and murine Bcrp1 or human BCRP. Paired PET scans were performed with (R)-[(11)C]verapamil in female FVB/N (wild-type), Mrp1((-/-)), Mdr1a/b((-/-)), Bcrp1((-/-)) and Mdr1a/b((-/-))Bcrp1((-/-)) mice, before and after Pgp inhibition with 15 mg/kg tariquidar.

Results: In vitro transport experiments exclusively showed directed transport of [(3)H]verapamil in Mdr1a- and MDR1-overexpressing cells which could be inhibited by tariquidar (0.5μM). In PET scans acquired before tariquidar administration, brain-to-blood ratio (Kb,brain) of (R)-[(11)C]verapamil was low in wild-type (1.3 ± 0.1), Mrp1((-/-)) (1.4 ± 0.1) and Bcrp1((-/-)) mice (1.8 ± 0.1) and high in Mdr1a/b((-/-)) (6.9 ± 0.8) and Mdr1a/b((-/-))Bcrp1((-/-)) mice (7.9 ± 0.5). In PET scans after tariquidar administration, Kb,brain was significantly increased in Pgp-expressing mice (wild-type: 5.0 ± 0.3-fold, Mrp1((-/-)): 3.2 ± 0.6-fold, Bcrp1((-/-)): 4.3 ± 0.1-fold) but not in Pgp knockout mice (Mdr1a/b((-/-)) and Mdr1a/b((-/-))Bcrp1((-/-))).

Conclusion: Our combined in vitro and in vivo data demonstrate that verapamil, in nanomolar concentrations, is selectively transported by Pgp and not by MRP1 and BCRP at the BBB, which supports the use of (R)-[(11)C]verapamil or racemic [(11)C]verapamil as PET tracers of cerebral Pgp function.

Citing Articles

ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.

Lentzas A, de Gooijer M, Zuidema S, Meurs A, Citirikkaya C, Venekamp N Fluids Barriers CNS. 2024; 21(1):62.

PMID: 39103921 PMC: 11301932. DOI: 10.1186/s12987-024-00562-4.

Performance and Sensitivity of [Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver.

Hernandez-Lozano I, Leterrier S, Mairinger S, Stanek J, Zacher A, Breyer L Mol Pharm. 2024; 21(2):932-943.

PMID: 38225758 PMC: 10848257. DOI: 10.1021/acs.molpharmaceut.3c01036.

Genetics of in Cancer.

Skinner K, Palkar A, Hong A Cancers (Basel). 2023; 15(17).

PMID: 37686513 PMC: 10487083. DOI: 10.3390/cancers15174236.

In vivo methods for imaging blood-brain barrier function and dysfunction.

Harris W, Asselin M, Hinz R, Parkes L, Allan S, Schiessl I Eur J Nucl Med Mol Imaging. 2022; 50(4):1051-1083.

PMID: 36437425 PMC: 9931809. DOI: 10.1007/s00259-022-05997-1.

Quantification of Engagement of Microtubules by Small Molecules in Living Cells by Flow Cytometry.

Andres A, Mariano A, Rane D, Peterson B ACS Bio Med Chem Au. 2022; 2(5):529-537.

PMID: 36281300 PMC: 9585582. DOI: 10.1021/acsbiomedchemau.2c00031.

References

Crivellato E, Candussio L, Rosati A, Mallardi F, Decorti G . The fluorescent probe Bodipy-FL-verapamil is a substrate for both P-glycoprotein and multidrug resistance-related protein (MRP)-1. J Histochem Cytochem. 2002; 50(5):731-4. DOI: 10.1177/002215540205000514. View

Sane R, Agarwal S, Mittapalli R, Elmquist W . Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system. J Pharmacol Exp Ther. 2013; 345(1):111-24. PMC: 3608446. DOI: 10.1124/jpet.112.199786. View

Sugiyama D, Kusuhara H, Lee Y, Sugiyama Y . Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier. Pharm Res. 2003; 20(9):1394-400. DOI: 10.1023/a:1025749925541. View

van Assema D, Lubberink M, Bauer M, van der Flier W, Schuit R, Windhorst A . Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain. 2011; 135(Pt 1):181-9. DOI: 10.1093/brain/awr298. View

Wagner C, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P . A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med. 2009; 50(12):1954-61. PMC: 3690436. DOI: 10.2967/jnumed.109.063289. View

Luurtsema G, Molthoff C, Schuit R, Windhorst A, Lammertsma A, Franssen E . Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol. 2005; 32(1):87-93. DOI: 10.1016/j.nucmedbio.2004.06.007. View

Warr J, Anderson M, Fergusson J . Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells. Cancer Res. 1988; 48(16):4477-83. View

Loscher W, Luna-Tortos C, Romermann K, Fedrowitz M . Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des. 2011; 17(26):2808-28. DOI: 10.2174/138161211797440212. View

Wanek T, Kuntner C, Bankstahl J, Mairinger S, Bankstahl M, Stanek J . A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J Cereb Blood Flow Metab. 2012; 32(11):2002-11. PMC: 3493998. DOI: 10.1038/jcbfm.2012.112. View

10.

Matsson P, Englund G, Ahlin G, Bergstrom C, Norinder U, Artursson P . A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther. 2007; 323(1):19-30. DOI: 10.1124/jpet.107.124768. View

11.

Syvanen S, Blomquist G, Sprycha M, Hoglund A, Roman M, Eriksson O . Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage. 2006; 32(3):1134-41. DOI: 10.1016/j.neuroimage.2006.05.047. View

12.

Poller B, Wagenaar E, Tang S, Schinkel A . Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011; 8(2):571-82. DOI: 10.1021/mp1003898. View

13.

Okamura T, Kikuchi T, Okada M, Toramatsu C, Fukushi K, Takei M . Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J Cereb Blood Flow Metab. 2008; 29(3):504-11. DOI: 10.1038/jcbfm.2008.135. View

14.

Bankstahl J, Bankstahl M, Romermann K, Wanek T, Stanek J, Windhorst A . Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metab Dispos. 2013; 41(4):754-62. DOI: 10.1124/dmd.112.049148. View

15.

Hendrikse N, Schinkel A, De Vries E, Fluks E, van der Graaf W, Willemsen A . Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol. 1998; 124(7):1413-8. PMC: 1565536. DOI: 10.1038/sj.bjp.0701979. View

16.

Shirasaka Y, Sakane T, Yamashita S . Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J Pharm Sci. 2007; 97(1):553-65. DOI: 10.1002/jps.21114. View

17.

Lee Y, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y . In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther. 2005; 316(2):647-53. DOI: 10.1124/jpet.105.088328. View

18.

Baltes S, Fedrowitz M, Tortos C, Potschka H, Loscher W . Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther. 2006; 320(1):331-43. DOI: 10.1124/jpet.106.102491. View

19.

Kortekaas R, Leenders K, van Oostrom J, Vaalburg W, Bart J, Willemsen A . Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005; 57(2):176-9. DOI: 10.1002/ana.20369. View

20.

Perrotton T, Trompier D, Chang X, Di Pietro A, Baubichon-Cortay H . (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem. 2007; 282(43):31542-8. DOI: 10.1074/jbc.M703964200. View